July 4 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES SUBMITS NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION) FOR FDA APPROVAL
* THERATECHNOLOGIES INC - FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR A SINGLE-VIAL FORMULATION OF EGRIFTA